iRadimed | 10-Q: FY2025 Q2 Revenue Beats Estimate at USD 20.41 M

LB filings
2025.08.01 20:07
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q2, the actual value is USD 20.41 M, beating the estimate of USD 20.01 M.

EPS: As of FY2025 Q2, the actual value is USD 0.45, beating the estimate of USD 0.395.

EBIT: As of FY2025 Q2, the actual value is USD 7.327 M, beating the estimate of USD 6.049 M.

Segment Revenue

  • Total Revenue: For the three months ended June 30, 2025, total revenue was $20.4 million, an increase of $2.5 million or 14% compared to $17.9 million for the same period in 2024. For the six months ended June 30, 2025, total revenue was $39.9 million, an increase of $4.4 million or 12% compared to $35.5 million for the same period in 2024.
  • Revenue by Geographic Region: Revenue from sales in the U.S. increased by $2.7 million, or 17%, to $18.2 million for the three months ended June 30, 2025, from $15.5 million for the same period in 2024. International sales decreased by $0.2 million, or 8%, to $2.2 million for the same period.
  • Revenue by Type: Revenue from sales of devices increased by $1.9 million, or 15%, to $14.6 million for the three months ended June 30, 2025, from $12.7 million for the same period in 2024. Revenue from disposables increased by $0.5 million, or 14%, to $4.2 million.

Operational Metrics

  • Net Income: For the three months ended June 30, 2025, net income was $5.8 million, compared to $4.9 million for the same period in 2024. For the six months ended June 30, 2025, net income was $10.5 million, compared to $9.0 million for the same period in 2024.
  • Gross Profit: Gross profit for the three months ended June 30, 2025 was $16.0 million, compared to $14.0 million for the same period in 2024. Gross profit margin remained at 78% for both periods.
  • Operating Expenses: General and administrative expenses for the three months ended June 30, 2025 were $4.3 million, compared to $4.1 million for the same period in 2024. Sales and marketing expenses were $4.0 million, compared to $3.5 million.

Cash Flow

  • Operating Cash Flow: Net cash provided by operating activities was $12.0 million for the six months ended June 30, 2025, compared to $10.5 million for the same period in 2024.
  • Investing Activities: Net cash used in investing activities was $6.7 million for the six months ended June 30, 2025, compared to $1.7 million for the same period in 2024.

Future Outlook and Strategy

  • Core Business Focus: The company expects higher revenue for the remainder of fiscal year 2025 compared to the same period in 2024, primarily due to increased sales of medical devices and products, related accessories, disposables, and services. Operating expenses are also expected to be higher due to increased sales and marketing, regulatory, and general administrative expenses.
  • Strategic Developments: The FDA has granted 510(k) clearance for the next-generation MRidium® 3870 IV infusion pump system, with an initial strategic rollout planned for the fourth quarter of 2025 and full commercial distribution throughout 2026.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.